Particles that deliver vaccines directly to mucosal surfaces could defend against many infectious diseases.
Many viruses and bacteria infect humans through mucosal surfaces, such as those in the lungs, gastrointestinal tract and reproductive tract. To help fight these pathogens, scientists are working on vaccines that can establish a front line of defense at mucosal surfaces.
Vaccines can be delivered to the lungs via an aerosol spray, but the lungs often clear away the vaccine before it can provoke an immune response. To overcome that, MIT engineers have developed a new type of nanoparticle that protects the vaccine long enough to generate a strong immune response — not only in the lungs, but also in mucosal surfaces far from the vaccination site, such as the gastrointestinal and reproductive tracts.
Such vaccines could help protect against influenza and other respiratory viruses, or prevent sexually transmitted diseases such as HIV, herpes simplex virus and human papilloma virus, says Darrell Irvine, an MIT professor of materials science and engineering and biological engineering and the leader of the research team. He is also exploring use of the particles to deliver cancer vaccines.
“This is a good example of a project where the same technology can be applied in cancer and in infectious disease. It’s a platform technology to deliver a vaccine of interest,” says Irvine, who is a member of MIT’s Koch Institute for Integrative Cancer Research and the Ragon Institute of Massachusetts General Hospital, MIT and Harvard University.
Irvine and colleagues describe the nanoparticle vaccine in the Sept. 25 issue of Science Translational Medicine. Lead authors of the paper are recent PhD recipient Adrienne Li and former MIT postdoc James Moon.
Only a handful of mucosal vaccines have been approved for human use; the best-known example is the Sabin polio vaccine, which is given orally and absorbed in the digestive tract. There is also a flu vaccine delivered by nasal spray, and mucosal vaccines against cholera, rotavirus and typhoid fever.
To create better ways of delivering such vaccines, Irvine and his colleagues built upon a nanoparticle they developed two years ago. The protein fragments that make up the vaccine are encased in a sphere made of several layers of lipids that are chemically “stapled” to one another, making the particles more durable inside the body.
“It’s like going from a soap bubble to a rubber tire. You have something that’s chemically much more resistant to disassembly,” Irvine says.
This allows the particles to resist disintegration once they reach the lungs. With this sturdier packaging, the protein vaccine remains in the lungs long enough for immune cells lining the surface of the lungs to grab them and deliver them to T cells. Activating T cells is a critical step for the immune system to form a memory of the vaccine particles so it will be primed to respond again during an infection.
Stopping the spread of infection
In studies of mice, the researchers found that HIV or cancer antigens encapsulated in nanoparticles were taken up by immune cells much more successfully than vaccine delivered to the lungs or under the skin without being trapped in nanoparticles.
HIV does not infect mice, so to test the immune response generated by the vaccines, the researchers infected the mice with a version of the vaccinia virus that was engineered to produce the HIV protein delivered by the vaccine.
Mice vaccinated with nanoparticles were able to quickly contain the virus and prevent it from escaping the lungs. Vaccinia virus usually spreads to the ovaries soon after infection, but the researchers found that the vaccinia virus in the ovaries of mice vaccinated with nanoparticles was undetectable, while substantial viral concentrations were found in mice that received other forms of the vaccine.
Mice that received the nanoparticle vaccine lost a small amount of weight after infection but then fully recovered, whereas the viral challenge was 100 percent lethal to mice who received the non-nanoparticle vaccine.
“Giving the vaccine at the mucosal surface in the nanocapsule form allowed us to completely block that systemic infection,” Irvine says.
The Latest on: Nanoparticle vaccine
- Seasonal Influenza Vaccines: Global Drug Forecast and Market Analysis to 2028on December 2, 2019 at 4:02 pm
In addition to new cell-based (Medicago's virus-like-particle VLP-vaccine MDG-2271) and recombinant influenza vaccines (Novavax's adjuvanted nanoparticle NanoFlu), universal influenza vaccines are ...
- Global Vaccine Adjuvants Market 2020-2024| Evolving Opportunities with Agenus Inc. and Avanti Polar Lipids Inc. | Technavioon November 22, 2019 at 4:10 pm
In addition, the development of nanoparticle adjuvants is anticipated to further boost the growth of the vaccine adjuvants market. Infants and children are prone to deadly diseases like hepatitis B, ...
- Nanoparticle Vaccine Offers Universal Protection Against influenza A Viruseson November 2, 2019 at 5:00 pm
However, this stalk domain itself isn't stable, so we used a very special way to make this vaccine construct with the stalk domain and had success. We assembled this stalk domain into a protein ...
- Novavax Begins Phase III Study on Influenza Vaccine Candidateon October 16, 2019 at 12:20 pm
Novavax, Inc. NVAX announced that it has initiated a phase III study on its nanoparticle seasonal influenza vaccine candidate NanoFlu. The pivotal study will evaluate the safety and immunogenicity of ...
- Novavax Initiates Pivotal Phase 3 Clinical Trial of NanoFlu Influenza Vaccine in Older Adultson October 15, 2019 at 4:01 am
About NanoFlu™ and Matrix-M™ NanoFlu is a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine produced by Novavax in its SF9 insect cell baculovirus system. NanoFlu uses HA amino ...
- Nanoparticles for RNA Vaccine Delivery Help Stop Melanoma Tumor Growthon October 1, 2019 at 7:44 am
To help with this, chemists at MIT have created a range of lipid nanoparticles that can be used as delivery vesicles for RNA vaccines. These nanoparticles have already been shown to improve target ...
- Delivery system can make RNA vaccines more powerfulon September 30, 2019 at 3:53 pm
MIT chemical engineers have developed a new type of lipid nanoparticle that can be used to deliver RNA vaccines. The particles also trigger the release of powerful immune signaling proteins that boost ...
- Nanocurcumin enhances BCG vaccine efficacyon September 21, 2019 at 12:24 pm
A study carried out on mice models has found that curcumin in nanoparticle form has the potential to enhance the efficacy of BCG vaccine such that it confers protection against adult pulmonary TB. The ...
- Researchers Develop Nanoparticle-Based Vaccine for Skin Canceron September 6, 2019 at 9:42 am
The vaccine—based on a novel nanoparticle—already has shown effective in preventing the development of melanoma in mice as well as in treating the initial tumors that result from the disease, ...
- Scientists demonstrate a new nano-vaccine preventing the spread of melanomaon August 5, 2019 at 9:41 pm
Developed by scientists at Tel Aviv University, the prospective vaccine encases two experimental new cancer drugs inside a tiny nanoparticle, with initial experiments revealing the therapy can both ...
via Google News and Bing News